Table 3.
Association of the rs66554220 variant (14 bp ID) genotype with non-segmental vitiligo features
| Clinical features | Inheritance models | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Allele | Co-dominant | Dominant | Recessive | ||||||
| Del n (%) | Ins n (%) | Del/Del n (%) | Del/Ins n (%) | Ins/Ins n (%) | Del/Del n (%) | Del/Ins+Ins/Ins n (%) | Del/Del+Del/Ins n (%) | Ins/Ins n (%) | |
| Triggering: | |||||||||
| Other(1) | 15 (44) | 18 (56) | 4 (12.12) | 21 (63.64) | 8 (24.24) | 4 (12.12) | 29 (87.88) | 25 (75.76) | 8 (24.24) |
| Stress | 67 (57) | 50 (43) | 43 (36.75) | 47 (40.17) | 27(23.08) | 43 (36.75) | 74 (63.25) | 90 (76.92) | 27 (23.08) |
| (χ2) p-value | Ref | n.s. | Ref | (8.18) 0.004 | n.s. | Ref | (7.26) 0.007 | Ref | n.s. |
| OR | 0.21 | 0.24 | |||||||
| [95% CI] | [0.07–0.66] | [0.08–0.72] | |||||||
| Familial clustering: | |||||||||
| No | 50 (59) | 34 (41) | 32 (38.09) | 35 (41.67) | 17 (20.24) | 32 (38.09) | 52 (61.91) | 67 (79.76) | 17 (20.24) |
| First grade | 14 (44) | 18 (56) | 8 (25) | 12 (37.50) | 12 (37.50) | 8 (25) | 24 (75) | 20 (62.50) | 12 (37.50) |
| (χ2) p-value | Ref | (4.31) 0.037 | Ref | n.s. | n.s. | Ref | n.s. | n.s. | n.s. |
| OR | 1.85 | ||||||||
| [95% CI] | [1.03–3.30] | ||||||||
| Initial macule time: | |||||||||
| Late onset (> 20 y) | 57 (51) | 54 (49) | 35 (31.53) | 44 (39.64) | 32 (28.83) | 35 (31.53) | 76 (68.47) | 79 (71.17) | 32 (28.83) |
| Early onset (< 20 y) | 52 (63) | 30 (37) | 29 (35.37) | 45 (54.88) | 8 (9.75) | 29 (35.37) | 53 (64.63) | 74 (90.25) | 8 (9.75) |
| (χ2) p-value | Ref | (5.03) 0.02 | Ref | n.s. | (6.88) 0.008 | Ref | n.s. | Ref | n.s. |
| OR | 0.63 | 0.30 | |||||||
| [95% CI] | [0.41–0.94] | [0.12–0.75] | |||||||
| Koebner’s phenomenon: | |||||||||
| No | 84 (59) | 58 (41) | 52 (36.62) | 63 (44.37) | 27 (19.01) | 52 (36.62) | 90 (63.38) | 115 (80.99) | 27 (19.01) |
| Yes | 22 (47) | 24 (53) | 10 (21.74) | 23 (50) | 13 (28.26) | 10 (21.74) | 36 (78.26) | 33 (71.74) | 13 (28.26) |
| (χ2) p-value | Ref | (4.10) 0.04 | Ref | n.s. | n.s. | Ref | n.s. | Ref | n.s. |
| OR | 1.63 | ||||||||
| [95% CI] | [1.01–2.61] | ||||||||
| Clinical subtype: | |||||||||
| Focal | 7 (30) | 15 (70) | 2 (9.10) | 9 (40.90) | 4 (50) | 2 (9.10) | 20 (90.9) | 11 (50) | 11 (50) |
| Acrofacial(2) | 12 (67) | 6 (33) | 9 (50) | 6 (33.33) | 3 (16.67) | 9 (50) | 9 (50) | 15 (83.33) | 3 (16.67) |
| Generalized(3) | 83 (55) | 67 (45) | 50 (33.33) | 66 (44) | 34 (22.67) | 50 (33.33) | 100 (66.67) | 116 (77.33) | 34 (22.67) |
| Universal(4) | 8 (54) | 6 (46) | 3 (21.42) | 9 (64.29) | 2 (14.29) | 3 (21.42) | 11 (78.58) | 12 (85.71) | 2 (14.29) |
| (χ2) p-value | Ref | (10.98) 0.001(2) | Ref | (4.55) 0.03(2) | (9) 0.003(2) | Ref | (8.31) 0.004(2) | Ref | (4.84) 0.03(2) |
| (10.22) 0.001(3) | (8.82) 0.002(3) | (5.35) 0.02(3) | (7.42) 0.006(3) | ||||||
| (4.16) 0.04(4) | (4.73) 0.03(4) | ||||||||
| OR | 0.21(2) | 0.15(2) | 0.06(2) | 0.10(2) | 5(2) | ||||
| 0.34(3) | 0.12(3) | 0.20(3) | 3.41(3) | ||||||
| 0.36(4) | 6(4) | ||||||||
| [95% CI] | [0.08–0.54](2) | [0.02–0.94](2) | [0.01–0.45](2) | [0.02–0.56](2) | [1.12–22.30](2) | ||||
| [0.17–0.67](3) | [0.03–0.59](3) | [0.05–0.89](3) | [1.36–8.55](3) | ||||||
| [0.14–0.97](4) | [1.08–33.32](4) | ||||||||
1
Included: injury, sun exposure and other diseases; in the clinical subtype, comparisons the significance are indicated in uppercase: 2 for focal vs acrofacial, 3 for focal vs generalized and 4 for focal vs. universal; χ2 – chi-square value; p-value – significance defined by χ2 test, OR – odds ratio, 95% CI – confidence interval of 95%, Ref – reference of baseline in comparisons made, n.s. – non-significant.